Symbols / ACXP Stock $2.01 +1.26% Acurx Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM

ACXP (Stock) Chart

O: — H: — L: — C: — V: —

SMA 20: — SMA 50: — SMA 200: —

Stock Fundamentals

Scroll to Statements

Index	EQUITY
Sector	Healthcare
Industry	Biotechnology
CEO	Mr. David P. Luci CPA, Esq., J.D.
Exch · Country	NCM · United States
Market Cap	5.72M
Enterprise Value	-1.90M
Income	-7.97M
Sales	—
FCF (ttm)	-4.29M
Book/sh	2.24
Cash/sh	2.65
Employees	4
Insider 10d	—
IPO	Jun 25, 2021

Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout	0.00%

P/E	—
Forward P/E	-0.91
PEG	—
P/S	—
P/B	0.89
P/C	—
EV/EBITDA	—
EV/Sales	—
Quick Ratio	3.14
Current Ratio	3.18
Debt/Eq	—
LT Debt/Eq	—

EPS (ttm)	-5.32
EPS next Y	-2.20
EPS Growth	—
Revenue Growth	—
EPS Gr Q/Q	—
Rev Gr Q/Q	—
Earnings (next)	2026-05-12
Earnings (prior)	2026-03-12
ROA	-87.60%
ROE	-270.80%
ROIC	—
Gross Margin	0.00%
Oper. Margin	0.00%
Profit Margin	0.00%

Shs Outstand	2.86M
Shs Float	2.76M
Insider Own	3.50%
Instit Own	5.91%
Short Float	3.48%
Short Ratio	0.07
Short Interest	94.77K
52W High	21.00
vs 52W High	-90.45%
52W Low	1.33
vs 52W Low	51.21%
Beta	-1.92
Impl. Vol.	—
Rel Volume	0.02
Avg Volume	3.17M
Volume	64.39K

Target (mean)	$17.00
Tgt Median	$10.00
Tgt Low	$10.00
Tgt High	$31.00
# Analysts	3
Recom	None
Prev Close	$1.98
Price	$2.00
Change	1.26%

About

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Forward $/yr	—	TTM $/yr	—	Yield %	—
5Y avg yield %	—	Avg FY yield (hist.)	—	CAGR 3Y / 5Y	—

Dividends per share by fiscal year (bars). Yields use FY total dividends divided by year-end weekly close (approximate). Orange dashed line: benchmark average yield (5Y Yahoo average when available, else trailing average of FY yields). Calendar YTD year uses a darker teal bar and a gold YTD marker on the yield line (YTD dividends are incomplete vs a full FY).

Dividend payout history

Yield % uses close on or before ex-date and assumes ~4 payments per year (approximate).

Ex-date	Amount	Yield %	Special

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus

$17.00

Mean price target

2. Current target

$2.02

Latest analyst target

3. DCF / Fair value

$-27.06

Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …

Ratings

Current target

$2.02

Low

$10.00

High

$31.00

Mean

$17.00

Latest analyst rating changes

Date	Action	Analyst	Rating Change	Price Target
2025-09-30	reit	HC Wainwright & Co.	Buy → Buy	$31
2025-08-12	main	HC Wainwright & Co.	Buy → Buy	$31
2025-03-19	reit	HC Wainwright & Co.	Buy → Buy	$12
2025-01-13	reit	HC Wainwright & Co.	Buy → Buy	$12
2025-01-10	reit	HC Wainwright & Co.	Buy → Buy	$12
2024-12-10	reit	HC Wainwright & Co.	Buy → Buy	$12
2024-11-14	reit	HC Wainwright & Co.	Buy → Buy	$12
2024-08-12	reit	HC Wainwright & Co.	Buy → Buy	$12
2024-05-16	reit	HC Wainwright & Co.	Buy → Buy	$12
2024-03-19	main	HC Wainwright & Co.	Buy → Buy	$12
2024-02-28	reit	HC Wainwright & Co.	Buy → Buy	$14
2023-12-15	main	HC Wainwright & Co.	Buy → Buy	$14
2023-11-15	reit	HC Wainwright & Co.	Buy → Buy	$13
2023-09-13	reit	HC Wainwright & Co.	Buy → Buy	$13
2023-08-15	main	HC Wainwright & Co.	Buy → Buy	$13
2023-05-15	reit	HC Wainwright & Co.	Buy → Buy	$14
2023-04-11	reit	HC Wainwright & Co.	— → Buy	$14
2023-03-17	reit	HC Wainwright & Co.	— → Buy	$14
2022-12-19	init	HC Wainwright & Co.	— → Buy	$14
2022-10-20	init	Alliance Global Partners	— → Buy	$14

News

RSS: Latest ACXP news

Acurx takes Wall Street stage at 48 Wall St. investor summit - Stock Titan Mon, 27 Apr 2026 12
Is Acurx Pharmaceuticals (ACXP) stock outpacing its medical peers this year? - MSN Sun, 26 Apr 2026 22
ACXP Forecast, Price Target & Analyst Ratings | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill Fri, 24 Apr 2026 07
Acurx Pharmaceuticals (ACXP) director awarded 37,100 stock options at $2.36 - Stock Titan Wed, 22 Apr 2026 20
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? - Yahoo Finance ue, 17 Mar 2026 07
Acurx Pharmaceuticals (ACXP) director awarded 2,150 stock options at $2.36 strike - Stock Titan Wed, 22 Apr 2026 20
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance ue, 06 Jan 2026 08
Acurx (NASDAQ: ACXP) director gets 2,150 stock options grant - Stock Titan Wed, 22 Apr 2026 20
Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term - Yahoo Finance Wed, 21 Jan 2026 08
Acurx (ACXP) director Carl Sailer awarded 2,150 stock options at $2.36 - Stock Titan Wed, 22 Apr 2026 20
Acurx Pharmaceuticals (ACXP) director awarded 2,150 stock options as board pay - Stock Titan Wed, 22 Apr 2026 20
Acurx Pharmaceuticals (ACXP) director receives 2,150 stock options grant - Stock Titan Wed, 22 Apr 2026 20
CFO of Acurx (NASDAQ: ACXP) receives 25,900 stock options award - Stock Titan Wed, 22 Apr 2026 20
Acurx Pharmaceuticals (ACXP) CEO awarded 37,100 stock options at $2.36 - Stock Titan Wed, 22 Apr 2026 20
Acurx pulls in $2.5M now, with another $4.6M tied to warrants - Stock Titan hu, 16 Apr 2026 07

Insider Transactions

Filed Date	Insider	Relationship	Transaction	Shares	Price	Value
2025-01-06	SCODARI JOSEPH C	Director	—	24,631	$1.02	$25,000
2025-01-06	DELUCCIA ROBERT J	Director and Beneficial Owner of more than 10% of a Class of Security	—	49,261	$1.02	$50,000
2025-01-06	LUCI DAVID P	Chief Executive Officer	—	49,261	$1.02	$50,000
2025-01-06	DEAN JACK H	Director	—	9,852	$1.02	$10,000
2025-01-06	DONOHUE JAMES J.	Director	—	9,852	$1.02	$10,000
2025-01-06	SAILER CARL	Director	—	24,631	$1.02	$25,000

Financials

Statement View

Line Item	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	0.00	0.00	0.00	0.00
Operating Revenue	0.00	0.00	0.00	0.00
Operating Expense	8.09 -42.70%	14.12 -3.12%	14.58 +20.55%	12.09
Research And Development	1.83 -66.05%	5.40 -10.59%	6.04 +27.12%	4.75
Selling General And Administration	6.26 -28.23%	8.72 +2.17%	8.53 +16.29%	7.34
General And Administrative Expense	6.26 -28.23%	8.72 +2.17%	8.53 +16.29%	7.34
Other Gand A	6.26 -28.23%	8.72 +2.17%	8.53 +16.29%	7.34
Total Expenses	8.09 -42.70%	14.12 -3.12%	14.58 +20.55%	12.09
Operating Income	-8.09 +42.70%	-14.12 +3.12%	-14.58 -20.55%	-12.09
EBITDA	-8.09 +42.70%	-14.12 +3.12%	-14.58 -20.55%	-12.09
Normalized EBITDA	-8.09 +42.70%	-14.12 +3.12%	-14.58 -20.55%	-12.09
EBIT	-8.09 +42.70%	-14.12 +3.12%	-14.58 -20.55%	-12.09
Total Unusual Items	—	—	—	0.00
Total Unusual Items Excluding Goodwill	—	—	—	0.00
Special Income Charges	—	—	—	0.00
Other Special Charges	—	—	—	—
Net Income	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Pretax Income	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Net Non Operating Interest Income Expense	0.13 +523.36%	0.02	—	—
Net Interest Income	0.13 +523.36%	0.02	—	—
Interest Income Non Operating	0.13 +523.36%	0.02	—	—
Interest Income	0.13 +523.36%	0.02	—	—
Other Income Expense	—	—	—	—
Tax Rate For Calcs	0.00	0.00	0.00	0.00
Tax Effect Of Unusual Items	0.00	0.00	0.00	0.00
Net Income Including Noncontrolling Interests	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Net Income From Continuing Operation Net Minority Interest	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Net Income From Continuing And Discontinued Operation	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Net Income Continuous Operations	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Normalized Income	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Net Income Common Stockholders	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Diluted EPS	—	-17.45 +24.13%	-23.00 -2.68%	-22.40
Basic EPS	—	-17.45 +24.13%	-23.00 -2.68%	-22.40
Basic Average Shares	—	0.81 +27.56%	0.63 +17.15%	0.54
Diluted Average Shares	—	0.81 +27.56%	0.63 +17.15%	0.54
Diluted NI Availto Com Stockholders	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09

Line Item	Trend	2023-12-31
Total Assets		7.71
Current Assets		7.71
Cash Cash Equivalents And Short Term Investments		7.47
Cash And Cash Equivalents		7.47
Cash Financial		7.47
Receivables		0.13
Other Receivables		0.13
Prepaid Assets		0.11
Total Non Current Assets		0.00
Total Liabilities Net Minority Interest		3.04
Current Liabilities		3.04
Payables And Accrued Expenses		2.33
Payables		0.00
Other Payable		0.00
Current Accrued Expenses		2.32
Pensionand Other Post Retirement Benefit Plans Current		0.72
Total Non Current Liabilities Net Minority Interest		0.00
Stockholders Equity		4.67
Common Stock Equity		4.67
Capital Stock		0.01
Common Stock		0.01
Share Issued		0.72
Ordinary Shares Number		0.72
Treasury Shares Number		0.00
Additional Paid In Capital		57.87
Retained Earnings		-53.22
Gains Losses Not Affecting Retained Earnings		—
Other Equity Adjustments		—
Total Equity Gross Minority Interest		4.67
Total Capitalization		4.67
Working Capital		4.67
Invested Capital		4.67
Net Tangible Assets		4.67
Tangible Book Value		4.67
Total Partnership Capital		-53.22

Line Item	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Cash Flow	-6.79 +34.63%	-10.38 -5.94%	-9.80 -29.95%	-7.54
Cash Flow From Continuing Operating Activities	-6.79 +34.63%	-10.38 -5.94%	-9.80 -29.95%	-7.54
Net Income From Continuing Operations	-7.97 +43.51%	-14.10 +3.26%	-14.58 -20.55%	-12.09
Other Non Cash Items	—	—	0.56 +29.93%	0.43
Pension And Employee Benefit Expense	—	—	—	0.00
Stock Based Compensation	1.57 -54.31%	3.44 -8.78%	3.77 +14.04%	3.30
Operating Gains Losses	—	—	—	—
Change In Working Capital	-0.39 -237.62%	0.28 -71.89%	1.01 -19.02%	1.25
Change In Receivables	0.00 -96.53%	0.08 +160.42%	-0.13	0.00
Change In Prepaid Assets	0.02 +167.20%	0.01 -96.45%	0.16 +424.50%	0.03
Change In Payables And Accrued Expense	-0.41 -303.98%	0.20 -79.57%	0.98 -19.46%	1.22
Financing Cash Flow	10.64 +60.78%	6.62 -18.96%	8.16 +120.92%	3.70
Cash Flow From Continuing Financing Activities	10.64 +60.78%	6.62 -18.96%	8.16 +120.92%	3.70
Net Issuance Payments Of Debt	—	—	—	—
Issuance Of Debt	—	—	—	—
Long Term Debt Issuance	—	—	—	—
Net Long Term Debt Issuance	—	—	—	—
Net Common Stock Issuance	6.80 +6.09%	6.41 +7.76%	5.94 +60.86%	3.70
Common Stock Payments	-0.00	0.00	—	—
Repurchase Of Capital Stock	-0.00	0.00	—	—
Proceeds From Stock Option Exercised	3.84 +1727.36%	0.21 -90.53%	2.22 +17069684.62%	0.00
Changes In Cash	3.85 +202.17%	-3.77 -130.07%	-1.64 +57.43%	-3.85
Beginning Cash Position	3.71 -50.41%	7.47 -17.97%	9.11 -29.69%	12.96
End Cash Position	7.56 +103.85%	3.71 -50.41%	7.47 -17.97%	9.11
Free Cash Flow	-6.79 +34.63%	-10.38 -5.94%	-9.80 -29.95%	-7.54
Common Stock Issuance	6.80 +6.11%	6.41 +7.76%	5.94 +60.86%	3.70
Issuance Of Capital Stock	6.80 +6.11%	6.41 +7.76%	5.94 +60.86%	3.70

SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

42026-04-22 View
42026-04-22 View
42026-04-22 View
42026-04-22 View
42026-04-22 View
42026-04-22 View
42026-04-22 View
42026-04-22 View
8-K2026-04-16 View
10-K2026-03-12 View
8-K2026-03-09 View
10-Q2025-11-12 View
8-K2025-09-22 View
8-K2025-09-19 View
10-Q2025-08-11 View
8-K2025-07-31 View
8-K2025-07-17 View
8-K2025-06-20 View
8-K2025-05-13 View
10-Q2025-05-12 View

Trades

Date	User	Broker	Pattern	Type	Position Size	Entry Price	Trade P&L	Status

Posts

Published	Title	Author	Category

Headers
`Ctrl`+`Alt`+`1` or `Ctrl`+`Shift`+`1`	Heading 1
`Ctrl`+`Alt`+`2` or `Ctrl`+`Shift`+`2`	Heading 2
`Ctrl`+`Alt`+`3` or `Ctrl`+`Shift`+`3`	Heading 3
Shift+digit may show `!` `@` `#` on US keyboards; those chords work too.
Formatting
`Ctrl`+`B`	Bold
`Ctrl`+`I`	Italic
`Ctrl`+`U`	Underline
`Ctrl`+`Z`	Undo
`Ctrl`+`Shift`+`Z`	Redo
`Ctrl`+`K`	Add link
`Tab`	Indent list
`Shift`+`Tab`	Outdent list